Reference
- CARACO, Y., TATEISHI, T., GUENGERICH, F. P. and WOOD, A. J. J., 1996, Microsomal codeine N-demethylation: cosegregation with cytochrome P450 3A4. Drug Metabolism and Disposition, 24, 761–764.
- CHANG, T. K. H., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, a-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437–442.
- CONE, E. J., PHELPS, B. A. and GORODETZKY, C. W., 1977, Urinary excretion of hydromorphone and metabolites in humans, rats, dogs, guinea pigs, and rabbits. Journal of Pharmaceutical Sciences, 66, 1709–1713.
- EDDY, N. B. and REID, J. G., 1934, Studies of morphine, codeine and their derivatives. Journal of Pharmacology and Experimental Therapeutics, 52, 468–493.
- GUENGERICH, F. P., 1999, Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology, 39, 1–17.
- KIRKWOOD, L. C., NATION, R. L. and SOMOGYI, A. A., 1997, Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. British Journal of Clinical Pharmacology, 44, 549–555.
- Ko, J. W., SUKHOVA, N., THACKER, D., CHEN, P. and FLOCKHART, D. A., 1997, Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition, 25, 853–862.
- LAWLOR, P., TURNER, K., HANSON, J. and BRUERA, E., 1997, Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain, 72, 79–85.
- LEE, C. R., GOLDSTEIN, J. A. and PIEPER, J. A., 2002, Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 12, 251–263.
- Liu, Z., MORTIMER, 0., SMITH, C. A., WOLF, C. R. and RANE, A., 1995, Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism. British Journal of Clinical Pharmacology, 39, 77–80.
- NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
- PRELUSKY, D. B., COUTTS, R. T. and PASUTTO, F. M., 1982, Stereospecific metabolic reduction of ketones. Journal of Pharmaceutical Sciences, 71, 1390–1393.
- RAPOPORT, H., NAUMAN, R., BISSEL, E. R. and BONNER, R. M., 1950, The preparation of some dihydro ketones in the morphine series by Oppenauer oxidation. Journal of Organic Chemistry, 15, 1103–1107.
- SCHMIDER, J., GREENBLATT, D. J., FOGELMAN, S. M., VON MOLTKE, L. L. and SHADER, R. I., 1997, Metabolism of dextromethorphan in vitro: involvement of cytochrome P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharmaceutics and Drug Disposition, 18, 227–240.
- SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
- WANG, R., NEWTON, D. J., Liu, N., ATKINS, W. M. and Lu, A. Y. H., 2000, Human cytochrome P450 3A4: in vitro drug—drug interaction patterns are substrate dependent. Drug Metabolism and Disposition, 28, 360–366.
- ZHENG, M., 1997, Isolation, identification and synthesis of hydromorphone metabolites: analysis and antinociceptive activities in comparison to morphine. PhD thesis, University of British Columbia, Vancouver.